Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
52
TRVI Quote, Financials, Valuation and Earnings
Last price:
$12.83
Seasonality move
:
59.04%
Day range:
$12.60 - $13.16
52-week range:
$3.47 - $14.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
8.68x
Volume:
1.2M
Avg. volume:
2.2M
1-year change:
205.23%
Market cap:
$1.6B
Revenue:
--
EPS (TTM):
-$0.37
Analysts' Opinion
-
Consensus RatingTrevi Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $21.30, Trevi Therapeutics, Inc. has an estimated upside of 65.76% from its current price of $12.85.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $12.85.
Fair Value
-
According to the consensus of 9 analysts, Trevi Therapeutics, Inc. has 65.76% upside to fair value with a price target of $21.30 per share.
TRVI vs. S&P 500
-
Over the past 5 trading days, Trevi Therapeutics, Inc. has overperformed the S&P 500 by 3.96% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Trevi Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Trevi Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Trevi Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Trevi Therapeutics, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Trevi Therapeutics, Inc. reported earnings per share of -$0.08.
Enterprise value:
1.5B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-3.20x
EV / Free cash flow:
-33.03x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$151K
Return On Assets:
-33.02%
Net Income Margin (TTM):
--
Return On Equity:
-35.48%
Return On Invested Capital:
-35.21%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$103K | -$144K | -$151K | -$36K | -$38K | |
| Operating Income | -$31.6M | -$48.2M | -$51.4M | -$14.1M | -$13.9M | |
| EBITDA | -$31.5M | -$48.1M | -$51.2M | -$14.1M | -$13.9M | |
| Diluted EPS | -$0.27 | -$0.44 | -$0.37 | -$0.13 | -$0.08 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $30.7M | $127.3M | $94M | $67.3M | $198.3M | |
| Total Assets | $31.6M | $128.4M | $95.9M | $68.9M | $199.4M | |
| Current Liabilities | $9.9M | $14.6M | $5.2M | $9.1M | $9M | |
| Total Liabilities | $20.2M | $18.5M | $6.3M | $9.9M | $9.6M | |
| Total Equity | $11.4M | $109.9M | $89.6M | $59M | $189.8M | |
| Total Debt | $14.6M | $10.8M | $1.2M | $878K | $527K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$31.7M | -$35.1M | -$44M | -$9.6M | -$10.9M | |
| Cash From Investing | -$1.7M | $15.2M | -$87.4M | $7.7M | -$50.9M | |
| Cash From Financing | -$7.2M | $10M | $172.2M | $5M | $1.6M | |
| Free Cash Flow | -$31.9M | -$35.1M | -$44M | -$9.6M | -$10.9M | |
TRVI
Sector
Market Cap
$1.6B
$28.2M
Price % of 52-Week High
89.3%
51.2%
Dividend Yield
0%
0%
Shareholder Yield
-15.5%
-1.54%
1-Year Price Total Return
205.23%
-18.1%
Beta (5-Year)
0.825
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$12.64
200-day SMA
Buy
Level
$8.26
Bollinger Bands (100)
Buy
Level
8.02 - 12.16
Chaikin Money Flow
Sell
Level
-130.6K
20-day SMA
Sell
Level
$13.01
Relative Strength Index (RSI14)
Buy
Level
54.27
ADX Line
Buy
Level
13.85
Williams %R
Neutral
Level
-62.0968
50-day SMA
Buy
Level
$11.86
MACD (12, 26)
Buy
Level
3.50
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
2.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (16.4702)
Sell
CA Score
(Annual)
Level (-0.9046)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (6.5856)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.
Stock Forecast FAQ
In the current month, TRVI has received 9 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TRVI average analyst price target in the past 3 months is $21.30.
-
Where Will Trevi Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Trevi Therapeutics, Inc. share price will rise to $21.30 per share over the next 12 months.
-
What Do Analysts Say About Trevi Therapeutics, Inc.?
Analysts are divided on their view about Trevi Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Trevi Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Trevi Therapeutics, Inc.'s Price Target?
The price target for Trevi Therapeutics, Inc. over the next 1-year time period is forecast to be $21.30 according to 9 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TRVI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Trevi Therapeutics, Inc. is a Buy. 9 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TRVI?
You can purchase shares of Trevi Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Trevi Therapeutics, Inc. shares.
-
What Is The Trevi Therapeutics, Inc. Share Price Today?
Trevi Therapeutics, Inc. was last trading at $12.83 per share. This represents the most recent stock quote for Trevi Therapeutics, Inc.. Yesterday, Trevi Therapeutics, Inc. closed at $12.85 per share.
-
How To Buy Trevi Therapeutics, Inc. Stock Online?
In order to purchase Trevi Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TRVI Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TRVI
Sector
P/E ratio
--
23.92x
PEG ratio
-3.20x
-0.01x
P/B ratio
8.68x
1.83x
Price / LTM sales
--
1.61x
Growth Metrics
TRVI
Sector
Revenue growth
--
4.6%
Earnings growth
37.8%
10.88%
Revenue (5-year growth)
--
6.46%
Earnings forecast
-$0.12
-$0.21
Profitability
TRVI
Sector
Profitability FY 2024
-$147K
$3.5M
Return on invested capital
-35.21%
-31.84%
Return on assets
-33.02%
-27.96%
Return on equity
-35.48%
-37.63%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
17
Estimated Next Earnings Date
Feb
12
Balance Sheet
TRVI
Sector
Total cash
$194.9M
$26.3M
Short term investments
$73.5M
$25.7M
Total assets
$110.9M
$76.9M
Long term debt
$527K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
